x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DCL-001223
| Product Information | |
|---|---|
| Organism | Human |
| Tissue | Pancreatic islets |
| Cell Type | Epithelial cells |
| Karyotype | Modal chromosome number 67-71 |
| Product Description | 1.2B4 is a hybrid cell line formed by the electrofusion of a primary culture of human pancreatic islets with HuP-T3, a human pancreatic carcinoma cell line. 1.2B4 has been shown to be tumourigenic when transplanted into a SCID mouse host. The cell line has applications in the study of pancreatic cell biology. 1.2B4 cells provide a method of producing pure insulin secreting cells when stimulated (please see attached protocols for the stimulation of insulin secretion). This is an alternative to the use of primary tissue in cell transplantation therapies for type 1 diabetes. |
| Format | Frozen |
| Growth Properties | Adherent |
| Shipping & Storage | |
|---|---|
| Shipping | Cryopreserved on dry ice. |
| Storage Instructions | Split sub-confluent cultures (70-80%) 1:2 to 1:6 i.e. seeding at 2-4 x 104 cells/cm2 using 0.05% trypsin or trypsin/EDTA; 5% CO2; 37 °C. Population doubling approx 20hrs. At confluence 105 cells/cm2 can be expected. |
| Storage Buffer/Media | RPMI-1640 + 2mM Glutamine + 10% FCS |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
